NCT04902027View on ClinicalTrials.gov

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

October 23, 2023

Study Completion Date

October 23, 2023

Conditions
Recurrent Head and Neck CancerMetastatic Head and Neck Cancer
Interventions
DRUG

Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)

All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY